CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 502 enrolled
Drug / intervention
Travatandrug
Likely dose
Travoprost 0.004% 1 drop each eye once dailyAI-extracted
Key inclusion· 2
  • ✓Adult patients of any race and either sex
  • ✓Chronic angle-closure glaucoma
Key exclusion· 0

None specified.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00051168
NCT00051168Phase 3Completed
CompareCT.gov

A Long-term Safety Study of Once-daily TRAVATAN

Alcon Research·interventional·Posted Jan 7, 2003·Updated Oct 7, 2011

In Brief

A Phase 3 clinical trial evaluating Travatan for Glaucoma, Open-angle and Ocular Hypertension. Completed, enrolled 502 participants across 1 site.

Detailed Summary

Long term safety study of TRAVATAN in patients with Open-angle glaucoma or ocular hypertension.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-angle, Ocular Hypertension
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 7, 2003
Enrollment StartJan 1, 2006
Primary CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 23.5 years ago

Interventions

Travatandrug

Travoprost (0.004%) 1 drop each eye once daily